Description
TARGIN 20mg/10mg Tablets Australia
TARGIN is a medication that combines two active ingredients: oxycodone and naloxone. It is typically prescribed for the management of moderate to severe pain, particularly in patients who require continuous, long-term opioid treatment.
In Australia, TARGIN is available in various strengths, including the 20mg/10mg formulation, which contains 20 mg of oxycodone and 10 mg of naloxone.
- Oxycodone: An opioid analgesic that provides pain relief by binding to opioid receptors in the brain and spinal cord.
- Naloxone: An opioid antagonist that helps mitigate some of the side effects associated with opioids, particularly constipation.
Indications
- TARGIN is used for the treatment of moderate to severe pain in patients who are tolerant to opioids, meaning they have already been exposed to opioids and require pain management.
Dosage and Administration
- TARGIN is typically taken orally and available in various strengths (e.g., TARGIN 5 mg/2.5 mg, 10 mg/5 mg, 20 mg/10 mg, 40 mg/20 mg).
- Patients should follow their healthcare provider’s instructions for dosing, as it may vary based on individual needs and response to treatment.
- Tablets should not be split, crushed, or chewed.
Side Effects
Common side effects can include:
- Nausea and vomiting
- Constipation
- Drowsiness or dizziness
- Dry mouth
- Headache
Serious side effects can include:
- Respiratory depression (trouble breathing)
- Severe sedation
- Allergic reactions
Warnings and Precautions
- Dependence and Addiction: Oxycodone can be addictive, and long-term use may lead to physical dependence. Patients should be monitored regularly.
- Respiratory Problems: Use with caution in individuals with respiratory issues, such as asthma or chronic obstructive pulmonary disease (COPD).
- Withdrawal Symptoms: Abrupt discontinuation may lead to withdrawal symptoms. It is advisable to taper off the medication under a physician’s guidance.
Contraindications
- TARGIN should not be used in individuals who are allergic to oxycodone, naloxone, or any of the excipients.
- It’s contraindicated in patients with severe respiratory depression, acute or severe bronchial asthma, or paralytic ileus.
Drug Interactions
TARGIN can interact with other medications, particularly:
- Other central nervous system (CNS) depressants (e.g., benzodiazepines, alcohol), which can enhance sedation and respiratory depression.
- Certain antidepressants and medications that may affect the metabolism of oxycodone.
Summary
TARGIN is an effective pain management option for patients requiring long-term opioid treatment while attempting to minimize some of the side effects associated with opioid therapy. It is crucial for patients to have regular check-ups with their healthcare provider to monitor their pain management and any potential side effects. If you have any questions or concerns about taking TARGIN, it’s essential to discuss them with your healthcare provider.
| Packaging Size |
25*10 Tablets
|
| Shelf life |
2029
|
| Brand |
Targin
|
| Manufacturer |
Mundipharma
|
| Minimum Order Quantity | Â 2 |
You are dealing with a legitimate supply.Product shelf life is till 2029
– They are Original. targin pill
– It comes with Complete package
– It’s Well packed and sealed in the original Company box.
– Competitive price with a discount if Purchased at a Large quantity. targin pill
Oxycodone/naloxone, sold under the brand name Targin among others, is a combination pain medication available as modified-release tablets administered by mouth.[5]
The oxycodone component is an opioid and is responsible for the pain-relieving effects
. Naloxone, an opioid antagonist,
opposes the effects of opioids but is poorly absorbed into the blood stream when administered orally; therefore, most of the dose remains in the gastrointestinal tract. This local presence reduces opioid-induced constipation by preventing oxycodone from binding to gut opioid receptors, without diminishing overall analgesic efficacy compared to oxycodone alone. A 2008 study demonstrated a significant reduction in constipation.[6] Oxycodone/naloxone was released in 2014 in the United States,[5] in 2006 in Germany, and has been available in some other European countries since 2009. In the United Kingdom, the 10 mg oxycodone / 5 mg naloxone and 20 mg / 10 mg strengths were approved in December 2008, and the 40 mg / 20 mg and 5 mg / 10 mg strengths received approval in July 2019.[7]
Preliminary evidence suggests that oxycodone/naloxone may be an effective treatment for severe, refractory restless legs syndrome if first-line therapies have not been effective.
Reviews
There are no reviews yet.